8-K: Pluri Inc. Secures $6.5 Million in Private Placement, Plans Kokomodo Acquisition

Pluri Inc. has entered into a securities purchase agreement for a $6.5 million private placement and a binding term sheet to acquire a majority stake in Kokomodo Ltd.

Summary

• Pluri Inc. has secured a $6.5 million private placement through a securities purchase agreement with Chutzpah Holdings Limited.
• The offering includes 1,383,948 common shares priced at $4.61 each, pre-funded warrants for 26,030 shares at $0.0001 each, and common warrants for 84,599 shares at $5.568 each.
• The pre-funded and common warrants are subject to a 19.99% beneficial ownership limitation until shareholder approval is obtained.
• Pluri Inc. also entered a binding term sheet to acquire approximately 71% of Kokomodo Ltd. for $4.5 million, payable in Pluri common shares.
• The Kokomodo transaction is contingent on due diligence, a definitive agreement, and shareholder approval.
• If the Kokomodo deal falls through, Pluri will purchase a portion of the investors Kokomodo shares for $1 million and invest an additional $500,000 in Kokomodo under a SAFE agreement.
• The private placement is expected to close around January 31, 2025, while the Kokomodo transaction is expected to close following shareholder approval.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining a successful capital raise and a strategic acquisition. However, there are risks associated with the closing of the transactions and the integration of Kokomodo, which temper the overall sentiment.

Positives

• The $6.5 million private placement provides Pluri Inc. with additional working capital.
• The acquisition of Kokomodo Ltd. could expand Pluri Inc.'s business and market presence.
• The appointment of Mr. Weinstein to the board brings experience in the pharmaceutical, biotechnology, and sustainable technology sectors.
• The pre-funded warrants allow for immediate funding with a nominal exercise price.

Negatives

• The common warrants have a higher exercise price of $5.568 per share, which may not be attractive to investors if the share price does not increase.
• The Kokomodo transaction is not guaranteed and is subject to several conditions, including shareholder approval.
• The potential for dilution of existing shares with the issuance of new shares for both the private placement and the Kokomodo acquisition.

Risks

• The closing of the private placement and the Kokomodo transaction are subject to customary closing conditions and may not be completed.
• The company may not be able to successfully complete due diligence for the Kokomodo transaction.
• Shareholder approval for the Kokomodo transaction may not be obtained.
• The company may face challenges in integrating Kokomodo Ltd. into its existing operations.
• The company's products may not be approved by regulatory agencies.
• The company may be unable to retain or attract key employees.
• Unforeseen scientific difficulties may develop with the company's processes.
• The company's products may wind up being more expensive than it anticipates.
• Results in the laboratory may not translate to equally good results in real clinical settings.
• The company's patents may not be sufficient.
• The company's products may harm recipients or consumers.
• Changes in legislation with an adverse impact may occur.
• Inability to timely develop and introduce new technologies, products and applications may occur.
• Loss of market share and pressure on pricing resulting from competition may occur.

Future Outlook

The company expects the private placement to close around January 31, 2025, and the Kokomodo transaction to close following shareholder approval. The company intends to use the proceeds from the private placement for working capital and general corporate purposes. The Kokomodo transaction is expected to close no later than the second or third quarter of 2025.

Management Comments

• The company intends to use the proceeds from the Offering for working capital and general corporate purposes.

Industry Context

This announcement reflects a trend of biotechnology companies seeking capital through private placements to fund operations and acquisitions. The acquisition of Kokomodo Ltd. suggests a strategic move to expand Pluri Inc.'s portfolio and market reach.

Comparison to Industry Standards

• The private placement structure, including common shares and warrants, is a common method for raising capital in the biotechnology sector.
• The valuation of Kokomodo Ltd. at $4.5 million for a 71% stake is within the range of similar acquisitions in the biotech industry, but the specific terms will depend on the due diligence findings.
• The use of a SAFE agreement with a discount and valuation cap in the event the Kokomodo acquisition does not close is a common practice in early-stage investments.
• The 19.99% beneficial ownership limitation on the warrants is a standard measure to prevent hostile takeovers and ensure compliance with securities regulations.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may see changes in the company's structure and operations due to the acquisition.
• Customers may benefit from the expanded product offerings and services.
• Suppliers may see increased business opportunities with the company.
• Creditors may be impacted by the company's increased debt and equity.

Next Steps

• The company will close the private placement, expected on or about January 31, 2025.
• The company will conduct due diligence on Kokomodo Ltd.
• The company will negotiate and execute a definitive agreement for the Kokomodo acquisition.
• The company will seek shareholder approval for the Kokomodo transaction.
• The company will file a registration statement for the resale of the securities issued in the private placement.

Key Dates

Keywords

private placement, securities purchase agreement, warrants, common shares, Kokomodo Ltd., acquisition, shareholder approval, working capital, biotechnology, pharmaceutical